<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="currently available evidence-based prophylactic treatment options for chronic migraine are" exact="topiramate" post="and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce"/>
 <result pre="of chronic migraine in Italy. Monoclonal antibodies that target the" exact="calcitonin" post="gene-related peptide (CGRP) pathway of migraine pathogenesis have been"/>
 <result pre="system structures and increased release of nociceptive neuropeptides, such as" exact="calcitonin" post="gene-related peptide (CGRP), which is highly expressed in trigeminal"/>
 <result pre="used in chronic migraine and emerging treatments in relation to" exact="calcitonin" post="gene-related peptide (CGRP). Modified with permission from Benemei, et"/>
 <result pre="physical therapies (e.g. acupuncture) and nutraceutical therapies (e.g. supplementary magnesium," exact="riboflavin" post="and Coenzyme Q10) can all be used to complement"/>
 <result pre="methysergide), antihypertensives (lisinopril, candesartan), and antidepressants that act as serotonin" exact="norepinephrine" post="reuptake inhibitors (venlafaxine), selective serotonin reuptake inhibitors (paroxetine, fluvoxamine)"/>
 <result pre="formulation of botulinum toxin A administered by intramuscular injection, and" exact="topiramate" post="are the only currently available therapies with high-quality evidence"/>
 <result pre="to be better tolerated than various oral prophylactic treatments, including" exact="topiramate" post="[ 50– 53]. Based on the PREEMPT clinical trial"/>
 <result pre="sensitisation, a key pathophysiological mechanisms of CM. Topiramate Like OBT-A," exact="topiramate" post="has the highest level of recommendation for the prophylactic"/>
 <result pre="treatment of CM in Italian treatment guidelines [ 41]. Although" exact="topiramate" post="reduced headache days versus placebo and was relatively well"/>
 <result pre="controlled trials [ 54, 55], adverse events commonly associated with" exact="topiramate" post="include paresthesia, memory and concentration disturbances, fatigue and nausea"/>
 <result pre="disturbances, fatigue and nausea [ 41]. It is believed that" exact="topiramate" post="is able to prevent the development of cortical spreading"/>
 <result pre="analysis of clinical trial results suggests that prophylactic treatment with" exact="topiramate" post="in patients with EM may help to prevent migraine"/>
 <result pre="C Caproni S Pisani A et al. Critical role of" exact="calcitonin" post="gene-related peptide receptors in cortical spreading depression Proc Natl"/>
 <result pre="C Cardeal M Melo A Botulinum toxin type a versus" exact="amitriptyline" post="for the treatment of chronic daily migraine Clin Neurol"/>
 <result pre="NT Jaffri SF A double-blind comparison of onabotulinumtoxina (BOTOX) and" exact="topiramate" post="(TOPAMAX) for the prophylactic treatment of chronic migraine: a"/>
 <result pre="Ramadan N Mathew N et al. Efficacy and safety of" exact="topiramate" post="for the treatment of chronic migraine: a randomized, double-blind,"/>
 <result pre="DA Morris BA Frost M et al. Rimegepant, an oral" exact="calcitonin" post="gene–related peptide receptor antagonist, for migraine N Engl J"/>
</results>
